Riskpilot← Back to searchSign inGet full accessBainan Biotech ApS
APSBankruptCVR 39904276Ole Maaløes Vej 3, 3.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20182 employees
Revenue 2023
DKK -382K
-69% vs 2022
EBITDA margin
149.5%
+83% vs 2022
Equity ratio
-521.6%
Financial strength
Net profit 2023
DKK -2,7M
+15% vs 2022
| Revenue | DKK -382K | -69% |
| EBITDA | DKK -571K | +83% |
| Net profit | DKK -2,7M | +15% |
| Total assets | DKK 2,9M | -21% |
| Equity | DKK -15,2M | -21% |
| Employees | 2 | — |
Legal name
Bainan Biotech ApS
CVR number
39904276
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. september 2018
Share capital
DKK 50.000
Employees
2 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem i forening med direktøren, af 2 bestyrelsesmedlemmer i forening eller af den
samlede bestyrelse.
Company purpose
Selskabets formål er forskning og udvikling af produkter inden for medicinindustrien samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed.
Address
Ole Maaløes Vej 3, 3.
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 421 | 1.953 | -3.710 | -1.230 | -382 |
| Staff expenses | -271 | -2.047 | -4.959 | -2.090 | -189 |
| EBITDA | 150 | -94 | -8.669 | -3.320 | -571 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 150 | -94 | -8.669 | -3.320 | -571 |
| Net financials | -5 | -969 | -1.965 | -558 | -2.149 |
| Profit before tax | 145 | -1.063 | -10.634 | -3.878 | -2.720 |
| Tax | 37 | -554 | -1.570 | -750 | -48 |
| Net profit | 109 | -510 | -9.064 | -3.129 | -2.672 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 2.237 | 13.555 | 5.646 | 3.708 | 2.917 |
| Equity | 159 | -351 | -9.415 | -12.544 | -15.216 |
| Long-term debt | 0 | 10.553 | 12.148 | 5.905 | 6.035 |
| Short-term debt | 2.078 | 3.353 | 2.913 | 10.347 | 12.097 |
| Total debt | 2.078 | 13.906 | 15.061 | 16.252 | 18.133 |
EBITDA margin
-57132100.0%
This company
15.8%
Market median
-361595670% vs market
20192023
Equity ratio
-521.6%
This company
38.2%
Market median
-1465% vs market
20192023
Return on equity
-267197700.0%
This company
18.4%
Market median
-1452161513% vs market
20192023
Net profit margin
-267197700.0%
This company
8.1%
Market median
-3298737137% vs market
20192023
Asset turnover
-0.13×
This company
1.12×
Market median
-112% vs market
20192023
Debt / equity
1.19×
This company
0.62×
Market median
-92% vs market
20192023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-09-27 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BH Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
TA Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
DR Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MM Rosenkilde ApS | Company | 25.0% | 25.0% | 2018 |
B Hartmann Holding ApS | Company | 25.0% | 25.0% | 2018 |
Vivopharm Holding ApS | Company | 10.0% | 10.0% | 2024 |
J Kryger Holding ApS | Company | 10.0% | 10.0% | 2024 |
JJ Holst ApS | Company | 10.0% | 10.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MM Rosenkilde ApS
Bainan Biotech ApS Board members of Bainan Biotech ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bolette Hartmann | Chief Executive Officer | 0 companies |
| Tue Alexander Emborg | Chief Executive Officer | 0 companies |
| Ditte Riber | Chief Executive Officer | 0 companies |
| Jens Juul Holst | Board of Directors | 0 companies |
| Mette Marie Rosenkilde | Chairman | 0 companies |
| Arvind Mansha Hundal | Board of Directors | 0 companies |